Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837196 · ClinicalTrials.gov registry record · Phase 1
Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
A Phase 1 study of Advanced Cancer and Advanced Malignancies, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT04837196 is a Phase 1 study of Advanced Cancer and Advanced Malignancies that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 24 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04837196, a Phase 1 study of Advanced Cancer and Advanced Malignancies, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study was to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab. This study also evaluated other measures of anticancer activity of ASP7517 when administered as a single agent and in combination with pembrolizumab based on central and local assessment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ASP7517
Study Locations (4)
Georgia
- Emory University - Atlanta
Illinois
- University of Chicago - Chicago
Iowa
- University of Iowa Hospitals - Iowa City
Pennsylvania
- UPCI Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-11-11 |
| Est. Completion | 2024-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04837196
The ClinicalTrials.gov registry entry for NCT04837196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04837196 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Illinois, Iowa.
Frequently Asked Questions
What is clinical trial NCT04837196 about?
NCT04837196 is a clinical study titled "Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen". The purpose of this study was to evaluate the safety, tolerability, and clinical response of ASP7517, and determine the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of ASP7517 when administered as a single agent and in combination with pembrolizumab. This study also evalu...
What is the current status of trial NCT04837196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2021-11-11. Estimated completion is 2024-06-21.
What conditions does trial NCT04837196 study?
This clinical trial studies the following conditions: Advanced Cancer, Advanced Malignancies.
What interventions are being tested in trial NCT04837196?
The interventions under investigation include: Pembrolizumab (DRUG), ASP7517 (DRUG).
Who is sponsoring clinical trial NCT04837196?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04837196 being conducted?
This trial has 4 study locations across Georgia, Illinois, Iowa, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.